Admission Kidney Tubule Biomarkers Do Not Predict Acute Kidney Injury or In-Hospital Adverse Events in Acute Heart...

Area of Science:

• Nephrology
• Cardiology
• Biomarker Research

Background:

• Serum creatinine commonly increases in patients hospitalized for acute heart failure (AHF) with acute kidney injury (AKI).
• The clinical significance of these creatinine elevations is variable.
• Predicting these changes and associated adverse events is crucial for patient management.

Purpose of the Study:

• To evaluate the association between admission levels of kidney tubule and cardiac biomarkers and increases in serum creatinine.
• To determine if these biomarkers predict adverse in-hospital events in patients with AHF and AKI.
• To understand the nature of creatinine changes in the context of AHF.

Main Methods:

• A nested case-control study was conducted using data from the Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study.
• 214 patients with stage 1 AKI within seven days of admission were matched with 214 controls without AKI.
• Logistic regression and ROC-AUC analysis assessed associations of 20 biomarkers with AKI, severe AKI, and adverse in-hospital events.

Main Results:

• Neither fractional excretion of sodium (FeNa) nor urinary MCP-1 were significantly associated with AKI risk, with poor discrimination (ROC-AUC < 0.60).
• These biomarkers did not predict severe AKI (stages 2 or 3).
• Elevated B-type natriuretic peptide levels predicted a composite of adverse in-hospital events (OR 2.3, 95% CI 1.2-4.2).

Conclusions:

• Admission kidney tubule and cardiac biomarkers are not associated with the risk of creatinine increases in AHF.
• These biomarkers do not predict adverse in-hospital events in this patient population.
• Creatinine changes observed in AHF are likely functional in nature, rather than indicative of intrinsic kidney damage predicted by these specific biomarkers.